Gerd R. Hetzel
YOU?
Author Swipe
View article: Monitoring individualized glucose levels predicts risk for bradycardia in type 2 diabetes patients with chronic kidney disease: a pilot study
Monitoring individualized glucose levels predicts risk for bradycardia in type 2 diabetes patients with chronic kidney disease: a pilot study Open
View article: Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients
Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients Open
Key Points Immune response to the coronavirus disease 2019 vaccination is significantly reduced in patients with kidney failure compared with controls without kidney failure. After two vaccinations, kidney transplant recipients show the lo…
View article: TO013PROTEINURIA REDUCTION IN IGA NEPHROPATHY BY NEFECON, A TARGETED‑RELEASE FORMULATION OF BUDESONIDE - RESULTS FROM THE NEFIGAN TRIAL
TO013PROTEINURIA REDUCTION IN IGA NEPHROPATHY BY NEFECON, A TARGETED‑RELEASE FORMULATION OF BUDESONIDE - RESULTS FROM THE NEFIGAN TRIAL Open
View article: MP761CARRIAGE OF NASAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN HEMODIALYSIS PATIENTS: ANALYSIS OF HOSPITAL-BASED VERSUS SEPARATE DIALYSIS CENTERS
MP761CARRIAGE OF NASAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN HEMODIALYSIS PATIENTS: ANALYSIS OF HOSPITAL-BASED VERSUS SEPARATE DIALYSIS CENTERS Open
View article: Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial Open
View article: Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis
Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis Open
Dietary CF ingestion mitigates acute HD-induced and chronic endothelial dysfunction in patients with ESRD and thus, improves vascular function in this high-risk population. Larger clinical trials are warranted to test whether this translat…
View article: Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis
Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis Open
MIF is a dialyzable plasma component that is effectively filtrated during HD from the patient blood pool in large amounts. After removal of remarkable amounts of MIF during a single HD session, MIF plasma pool is early reconstituted after …